Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Cabo Verde.
Press releases published on July 30, 2025
Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy
GlobeNewswire
·
July 30, 2025
BERKELEY, Calif, July 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an …
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
GlobeNewswire
·
July 30, 2025
FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) -- Paragon Genomics, Inc., a global leader in target enrichment solutions for next-generation sequencing (NGS), and Genecast (Taizhou) Biotechnology Co., Ltd., a pioneering oncology …
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
GlobeNewswire
·
July 30, 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
GlobeNewswire
·
July 30, 2025
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ …
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
July 30, 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook …
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
July 30, 2025
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) …
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
GlobeNewswire
·
July 30, 2025
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA Presented additional analyses from the ATH434-201 trial …
NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
GlobeNewswire
·
July 30, 2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a …
Anika Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
July 30, 2025
Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results …
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
GlobeNewswire
·
July 30, 2025
Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a …
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
GlobeNewswire
·
July 30, 2025
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements …
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
GlobeNewswire
·
July 30, 2025
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from …
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
GlobeNewswire
·
July 30, 2025
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV …
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 30, 2025
RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing …
Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025
GlobeNewswire
·
July 30, 2025
BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results …
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 30, 2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
GlobeNewswire
·
July 30, 2025
MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve …
Amarin Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
July 30, 2025
-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects …
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
GlobeNewswire
·
July 30, 2025
POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will …
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
GlobeNewswire
·
July 30, 2025
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in- …